Maxime Jullien

17PUBLICATIONS
35CO-AUTHORS
Haematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)HaematologyEpidemiological methodsMedical biotechnology diagnostics (incl. biosensors)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Aug 20, 2026
Treosulfan or busulfan plus clofarabine as reduced intensity conditioning regimen before allotransplant for adults with myeloid malignancies.

|Oct 31, 2025
Functional recovery of NK cells after T-cell replete haploidentical HSCT: delayed licensing and poor anti-acute myeloid leukemia activity.

Maxime Jullien, Enora Ferron, Catherine Willem

|Sep 15, 2025
Thiotepa-busulfan-fludarabine compared to clofarabine-based conditioning for haploidentical transplant with posttransplant cyclophosphamide in patients with myeloid malignancies: a retrospective study from the SFGM-TC.

Maxime Jullien, Eolia Brissot, Etienne Daguindau

|Apr 16, 2025
Posaconazole versus fluconazole as primary antifungal prophylaxis for patients at high risk of invasive fungal infections receiving allogeneic hematopoietic stem cell transplantation.

Valentin Letailleur, Maxime Jullien, Alice Garnier

|Sep 14, 2024
Deep Learning-Based Blood Abnormalities Detection as a Tool for VEXAS Syndrome Screening.

Cédric De Almeida Braga, Maxence Bauvais, Pierre Sujobert

|Apr 13, 2024
Late Relapse after Allogeneic Stem Cell Transplantation in Patients Treated for Acute Myeloid Leukemia: Relapse Incidence, Characteristics, Role of Conditioning Regimen, and Outcome.

Chloé Antier, Maxime Jullien, Benoît Tessoulin

Pageof 3

Frequent Collaborators

12 joint publications

Patrice Chevallier

10 joint publications

Thierry Guillaume

5 joint publications

Pierre Peterlin

5 joint publications

Marie C Béné